Azitra, Inc. to Showcase Advances at H.C. Wainwright Annual Conference

Azitra, Inc. (NYSE American: AZTR), a pioneering clinical-stage biopharmaceutical company, is set to participate in the H.C. Wainwright 28th Annual Global Investment Conference scheduled from September 14-16, 2026, in New York City. The announcement comes on September 8, 2026, and is generating excitement within the investment and healthcare communities.

The event will feature a presentation by Travis Whitfill, Ph.D., MPH, Co-founder and Chief Operating Officer of Azitra. Dr. Whitfill's presentation will be pre-recorded, providing updates on the company's recent advancements and strategic pipeline developments, particularly focusing on the ATR-COSF program. This innovative program leverages microbial genetic engineering to expand Azitra’s reach beyond conventional therapeutics into aesthetic applications, including those that target fine lines and wrinkles.

The company's dedication to innovation is also evident in its clinical trials, specifically the ongoing Phase 1/2 study evaluating ATR-04, which addresses EGFR inhibitor-associated rashes that affect around 150,000 individuals in the U.S. Azitra has received Fast Track designation from the FDA for this condition, a significant step in expediting the development of therapies for patients in need.

Event Details

Event: H.C. Wainwright 28th Annual Global Investment Conference
Dates: September 14-16, 2026
Presenter: Travis Whitfill, Ph.D., MPH
Webcast Link: View Presentation Here

During the conference, Dr. Whitfill will not only present but will also engage in one-on-one meetings with registered investors and potential partners. This engagement will spotlight Azitra's business strategy, clinical development roadmap, milestones achieved, and upcoming objectives.

About Azitra, Inc.

Azitra, Inc. stands at the forefront of biopharmaceutical innovation, focusing on the development of advanced therapies in precision dermatology. The company's unique portfolio includes cutting-edge products like ATR-COSF and ATR-04, which underscore Azitra's commitment to deploying recombinant protein technologies for both therapeutic and cosmetic uses. Furthermore, Azitra is actively engaged in several projects aimed at supporting biotechnological research and manufacturing applications.

By harnessing a combination of engineered proteins, artificial intelligence, and proprietary microbial libraries, Azitra aims to create distinct solutions that cater to consumer needs within healthcare and research markets. With recent achievements and a clear vision for the future, Azitra continues to make strides in revolutionizing how dermatological conditions are treated.

For those interested in following the company's journey and accessing further details, Azitra encourages visits to its official site: Azitra Inc..

Looking Forward

As Azitra prepares for the conference, industry analysts and investors alike are keenly watching how their innovative strategies could reshape the landscape of dermatological treatments. The upcoming presentation and meetings will provide crucial insights into the company's pipeline developments, reflecting its potential impact on both the market and patient care. Azitra underscores that its journey is filled with possibilities, even while acknowledging the inherent risks associated with biopharmaceutical advancements.

In summary, Azitra's active role at the H.C. Wainwright Annual Global Investment Conference demonstrates its commitment to transparent communication with stakeholders and its eagerness to showcase its innovative pipeline. With a focus on patient-centered therapeutic solutions, Azitra is poised for growth in the burgeoning field of precision dermatology.